$1.55
-0.03-1.9%
Ult. Agg.: Oct 27, 6:02 PM
enGene Therapeutics (ENGN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | FY '23 |
|---|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||||
| Estimate | $-0.44 | $-0.47 | $-0.56 | $-0.57 | — |
| Actual | $-0.47 | $-0.43 | $-0.44 | $-0.73 | $-151.22 |
| Surprise | -6.82% | +8.51% | +21.4% | -28.1% | — |
| Revenue | |||||
| Estimate | — | — | — | — | — |
| Actual | $0 | $0 | $0 | $0 | $0 |
| Surprise | — | — | — | — | — |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.46 | $-0.34 | $-0.37 | $-0.37 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Sep 8, 2026 | $-0.47 | $-0.44 | -6.82 % |
| Q2 | Jun 15, 2026 | $-0.43 | $-0.47 | 8.51 % |
| Q1 | Mar 9, 2026 | $-0.44 | $-0.56 | 21.4 % |
| Q4 | Dec 22, 2025 | $-0.73 | $-0.57 | -28.1 % |